Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Vital Genes in Fat Production Found

By Drug Discovery Trends Editor | June 16, 2015

Human brown fat progenitor cells express the calorie-burning, UCP1 proteins (green) as the cell differentiates. (Credit: Tseng Laboratory, Joslin Diabetes Center )Harvard Stem Cell Institute (HSCI) scientists have found a way to both make more energy-burning human brown fat cells and make the cells themselves more active, a discovery that could have therapeutic potential for diabetes, obesity, and other metabolic diseases.
 
Unlike energy-storing white, or “bad,” fat cells, “good” brown fat cells make a protein called UCP1 that converts energy stored in glucose and fatty acids into heat to keep the body warm. When active, brown fat cells can also use energy stored by white fat cells, and as a result reduce the size of nearby white fat cells.
 
The research team, made up of scientists at Harvard University and at Harvard-affiliated Joslin Diabetes Center and led by HSCI principal faculty member Yu-Hua Tseng, determined that the amount of energy burned varies from person to person and from cell to cell. As it turns out, said Tseng, “Not all fat cells are created equal.”
 
The researchers determined that a whole suite of genes help determine how much UCP1 a brown fat cell will produce once it has matured, and those genes control UCP1 production in different ways. Some, Tseng said, act like on/off switches: When the gene is on, a brown fat cell can make the energy-burning protein, and when it is turned off, it doesn’t. Other genes acted more like a light dimmer that adjusts or fine tunes the amount of UPC1 created.
 
The research was published online today in the journal Nature Medicine. Tseng collaborated with HSCI’s Lee Rubin and researchers at the National Institutes of Health, the Joslin, Boston University, Beth Israel Deaconess Hospital, and Fudan University in China.
 
Knowing which genes control UCP1 should help scientists develop therapies. “We could take fat samples from patients undergoing liposuction and we could purify this specific population of progenitor cells,” keeping only those that would eventually make highly active brown fat cells, “and let them differentiate into brown cells, and then get them back into the individual,” Tseng said. Once reintroduced to the patient’s body, the additional brown fat cells would burn energy from the existing white fat cells.
 
Tseng hopes this technique could eventually replace invasive procedures such as liposuction and gastric bypass surgery. While liposuction removes white fat cells, it does not make the brown fat cells more efficient. And gastric bypass, though life-saving, can be risky. Tseng believes cell therapy would be “much safer and much less invasive.”
 
Controlling the genes might allow scientists to make mediocre brown fat cells work better. This could potentially allow the brown fat cells to remove the high numbers of circulating glucose associated with type 2 diabetes and circulating fatty acids and triglycerides that are the hallmark of metabolic syndrome.
 
“By further understanding how adipose cells become thermogenically active, meaning they use energy to produce heat and thus burn calories, we may discover novel therapeutics for the treatment of obesity and metabolic disease,” said Chad Cowan, an HSCI principal faculty member who, among other things, also studies the therapeutic potential of brown fat cells.
 
In 2014, Cowan identified two drugs with the potential to convert stem cells that make white fat into those that would make brown. “This latest study gives us new tools and targets to use in the battle against obesity,” Cowan said.
 
Source: Harvard University

Filed Under: Genomics/Proteomics

 

Related Articles Read More >

Spatial biology: Transforming our understanding of cellular environments
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
DNA helix 3D illustration. Mutations under microscope. Decoding genome. Virtual modeling of chemical processes. Hi-tech in medicine
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
A media release and Scientific Report image of Elizabeth Kellogg. - Camera Settings: ILCE-9M2, 12mm, ISO 1000, 1/80, f/3.2, Fri, 04-19-2024 at 10:10. v.12.01.23
St. Jude pioneers gene editing and structural biology to advance pediatric research
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE